04 March 2022
: Case report 
Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report
Unusual setting of medical care
Takatsugu Ogata1ABCDEF, Yasuko Fujita
2BCD, Kei Muro1ABCDE*
DOI: 10.12659/AJCR.935600
Am J Case Rep 2022; 23:e935600
Table 1. Treatment history before the T-DXd rechallenge.
| Line | 1st | 2nd | 3rd | 4th | 5th | 6th |
|---|---|---|---|---|---|---|
| Regimen | SOX+Tmab | PTX+Ram | IRI | T-DXd | ICI-based | Nivo |
| Treatment period (months) | 12.9 | 5.1 | 5.3 | 5.6 | 6.9 | 2.1 |
| Best of response | PR | PR | SD | PR | PR | PD |
| ICI – immune checkpoint inhibitor; IRI – irinotecan; Nivo – nivolumab; PD – progressive disease; PR – partial response; PTX – paclitaxel; Ram – ramucirumab; SD – stable disease; SOX – S-1+oxaliplatin; T-DXd – trastuzumab deruxtecan; Tmab – trastuzumab. | ||||||